{"id":"suboxone-sch-000484","safety":{"commonSideEffects":[{"rate":"~10–20%","effect":"Headache"},{"rate":"~10–15%","effect":"Constipation"},{"rate":"~5–10%","effect":"Nausea"},{"rate":"~5–10%","effect":"Insomnia"},{"rate":"~5–10%","effect":"Sweating"},{"rate":null,"effect":"Withdrawal symptoms (if inadequately dosed)"},{"rate":null,"effect":"Respiratory depression (at high doses)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Buprenorphine binds with high affinity to mu-opioid receptors, providing partial agonist activity that alleviates withdrawal symptoms and cravings with a lower overdose risk than full opioid agonists. Naloxone, included as a deterrent to intravenous misuse, blocks opioid receptors and precipitates withdrawal if the combination is injected. Together, these components enable maintenance treatment for opioid use disorder with reduced abuse liability.","oneSentence":"Suboxone is a combination of buprenorphine (a partial opioid agonist) and naloxone (an opioid antagonist) that reduces opioid cravings and withdrawal symptoms while minimizing abuse potential.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:38:14.683Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Opioid use disorder maintenance treatment"},{"name":"Opioid dependence"}]},"trialDetails":[{"nctId":"NCT00684073","phase":"PHASE4","title":"Preference for Subutex® (Buprenorphine) Versus Suboxone® (Buprenorphine/Naloxone) in Opioid Dependent Patients on Subutex® (Study P05094)(COMPLETED)","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2007-07","conditions":"Opiate-related Disorders, Opiate Dependence, Drug Abuse","enrollment":60},{"nctId":"NCT00604188","phase":"PHASE4","title":"A Randomized Acceptability and Safety Study of Suboxone Induction in Heroin Users (P05042)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-02-22","conditions":"Opiate Dependence, Drug Dependence, Substance Dependence","enrollment":188},{"nctId":"NCT00725608","phase":"","title":"Acceptability and Safety of Switching From Subutex or Other Opioid Drug Dependence Therapy to Suboxone (NIS P05444)","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2008-05","conditions":"Opioid-Related Disorders, Opiate Dependence, Drug Abuse","enrollment":339},{"nctId":"NCT00723749","phase":"","title":"Treatment of Opioid Dependent Patients With Suboxone: Acceptability & Safety Data From Real Life Scenario (Study P05603)","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2008-03","conditions":"Opioid-Related Disorders, Opiate Dependence, Drug Abuse","enrollment":384}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["SCH 000484"],"phase":"marketed","status":"active","brandName":"Suboxone (SCH 000484)","genericName":"Suboxone (SCH 000484)","companyName":"Merck Sharp & Dohme LLC","companyId":"merck","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Suboxone is a combination of buprenorphine (a partial opioid agonist) and naloxone (an opioid antagonist) that reduces opioid cravings and withdrawal symptoms while minimizing abuse potential. Used for Opioid use disorder maintenance treatment, Opioid dependence.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}